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Background: Application of the sentinel node concept to lung cancer is still
controversial. Patients with peripheral small lung cancers would gain the most
benefit from this concept, if it were valid. We sought to determine whether it is
possible to choose between limited lymph node sampling and systematic lymphad-
enectomy from the distribution of sentinel lymph nodes in patients with node-
negative disease on the basis of imaging.
Methods: Sixty-five consecutive patients with cT1 N0 M0 non–small cell lung
cancer were enrolled. A radioisotope tracer (4 mCi of technetium-99m tin colloid,
2.0 mL) was injected in the vicinity of the tumor before surgical intervention with
computed tomographic guidance. The radioactivity of each resected lymph node
was measured separately with a hand-held gamma probe after complete tumor
resection. Sentinel nodes were identified, and the accuracy of sentinel node mapping
was examined. Whether the location of the sentinel node depended on the site of the
primary tumor was also examined.
Results: Of the 65 patients, 3 were excluded because of the final pathologic results.
Successful radionuclide migration occurred in 39 (62.9%) of the 62 patients. There
was 1 (2.6%) false-negative result among 39 patients with a sentinel node, and
therefore the sensitivity was 90%, and the specificity was 100%. The most common
sentinel lymph nodes were at level 12 (46.7%), followed by level 11 (18.3%), the
mediastinum (16.7%), and level 10 (11.7%).
Conclusion: The sentinel node concept is valid in patients with cT1 N0 M0 lung
cancer. The lobar lymph nodes were identified as sentinel nodes more frequently
than other lymph nodes. We need to make further efforts to increase the sentinel
node identification rate. However, we believe that if sentinel nodes are identified,
sentinel node mapping can allow the accurate intraoperative diagnosis of pathologic
N0 status in patients with cT1 N0 M0 lung cancer.
The sentinel node (SN) has been defined as being the “first lymphnode that receives afferent lymphatic drainage from a primary tu-mor,”1 and therefore this node should be the first site of lymphaticinvolvement if metastases have occurred. The histology of the SN isassumed to reflect the histology of the reminder of the nodal basin.Thus validation of the SN technique might allow accurate intraop-
erative identification of nodal involvement at the first lymphatic drainage site and
potentially segregate patients who might require complete nodal dissection to
remove further disease from those in whom more focused resection can be done as
a result of negative SNs. The presence of larger tumors and grossly enlarged lymph
nodes might cause lymphatic obstruction or alter the lymphatic channels, but
sampling the SN in patients who have small tumors without adenopathy (cT1 N0
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M0) could permit regional lymph node staging and avoid
the need for lymphadenectomy. Another benefit of SN de-
tection is that this technique might allow better understand-
ing of common drainage patterns from different tumor lo-
cations. On the basis of a detailed analysis of SNs in patients
with cT1 N0 M0 lung cancer at various locations, reevalu-
ation of the lymphatic vessels might be possible.
The 2 purposes of this study were to (1) assess the ability
of the SN technique to predict N0 disease in patients with
small tumors and (2) to evaluate the pathway of lymphatic
drainage.
Materials and Methods
Eligibility
This study was approved by the National Sanyo Hospital Investi-
gational Review Board for studies dealing with human subjects.
Sixty-five consecutive patients with clinical T1 N0 M0 non–small
cell lung cancer were enrolled after providing written informed
consent. Patients were excluded if enlarged mediastinal lymph
nodes were more than 1.0 cm in short-axis diameter on computed
tomography (CT) or if the primary tumor was larger than 3 cm in
size. Preoperative cervical mediastinoscopy was not performed in
any patient. Only patients able to tolerate anatomic resection of
their tumors and complete mediastinal node dissection were in-
cluded in the study.
Administration of Radioactive Colloid
In Japan the use of radioisotopes is strictly limited to designated
areas, and therefore the tracer could only be injected in a special
room. A radioisotope tracer was injected on the day before
surgical intervention, according to the following procedure.
First, in the CT room the site for injection was marked on the
skin, and the length of the needle required to reach the peritu-
moral region was determined (Figure 1, left). Then the patient
was taken to the radioisotope room, and a 22-gauge needle (15
cm long) was introduced at the point marked on the skin and
advanced to the peritumoral region on the basis of the depth
measured. Then 4 mCi of technetium tin colloid (in a volume of
2.0 mL) was injected as a bolus. Finally, the patient was taken
back to the CT room to confirm the proper location of the
injected radioisotope in the vicinity of the tumor (Figure 1,
right). The injected radioisotope was confirmed as an area of
ground-glass attenuation near the tumor.
Operative Technique
Standard lobectomy or segmentectomy combined with systematic
lymph node dissection was performed to achieve anatomic resec-
tion of the tumor.
Measurement of Radioactivity
The radioactivity of each dissected lymph node was measured
away from the operating field and separate from the tumor spec-
imen with a hand-held gamma probe (Navigator GPS; Auto Suture
Japan, Tokyo, Japan). The background radioactivity was measured
at the superior vena cava on the right side or at the descending
thoracic aorta on the left side. The level of radioactivity was
recorded for a 10-second period at each site.
Definition of an SN
Migration of the technetium tin colloid was considered successful
if a specific lymph node station registered more than 5 times the
background value of counts per second. If a lymph node station
was found to have the highest number of counts per second or
more than 50% of the highest number on ex vivo measurements
and the level was greater than 5 times the intrathoracic back-
ground, then that station was classified as the SN. The lymph node
nomenclature used was similar to that of the lymph node map for
lung cancer, which was reported previously.2
Figure 1. The scanner projected 6 parallel grids onto the skin as landmarks to determine the site for needle
insertion. The distance from the skin to the pleura or to the tumor was measured (left). After achievement of local
anesthesia, technetium 99m tin colloid was injected in the vicinity of the lesion with a 22-gauge needle.
Subsequently, the location of the injected technetium (arrow) and the lesion were confirmed by means of CT (right).
Injected radioisotope was confirmed as an area of ground-glass attenuation near the tumor.
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Pathologic Evaluation
After identification of the SN, the nodes were examined according
to a standard protocol. After formalin fixation and embedding in
paraffin, 2 or 3 sections were cut and stained with hematoxylin and
eosin. All resected nodes were examined by using conventional
techniques, with one or 2 sections stained with hematoxylin and
eosin being studied for each node. The nodes were not examined
by means of immunohistochemistry with cytokeratin.
Statistical Analysis
Results are presented as the mean  SD, and analysis of signifi-
cance was done with the unpaired t test.
Results
No significant complications of SN mapping were observed,
and preoperative radioisotope injection did not create a need
for tube drainage, except for slight intrapulmonary bleeding
and a very small pneumothorax in 1 and 7 patients, respec-
tively. Of the 65 patients, 3 were excluded from the study
because the final pathologic diagnosis was not primary lung
cancer (2 had metastatic lung cancer, and 1 had small cell
carcinoma).
Successful radionuclide migration occurred in 39
(62.9%) of the 62 patients with primary lung cancer. The
time between radioisotope injection and detection of SNs
was 1203  150 minutes (range, 990-1490 minutes). His-
topathologic examination detected metastatic disease in 10
(25.6%) of the 39 SNs that were examined. Nodal meta-
static disease was only present in 1 of the 23 patients in
whom the radionuclide did not migrate (this patient had N1
nodal metastases).
The characteristics of the 39 patients with identifiable
SNs and the features of the 23 patients without identifiable
SNs are shown in Table 1. The mean age was 63 12 years
for the patients with identifiable SNs, which was signifi-
cantly less than the age of 68  9 years for the patients
without SNs (P  .03). Forced expiratory volume in 1
second/forced vital capacity (FEV1.0%) was 74.5% 
11.0% in the patients without SNs, which was significantly
lower than the FEV1.0% of 81.2%  8.1% in patients with
SNs (P  .02).
The sensitivity of the SN technique was 90% (9/10), and
the specificity was 100%. A false-negative SN finding oc-
curred in 1 of 39 patients. This patient had a 28-mm tumor
in the left upper lobe. The SN was classified as being at
level 5, but histologic examination revealed that the only
positive nodes were located at level 12. An error in 1 of 39
patients resulted in a false-negative rate of 2.6%.
Of the 60 SNs identified in the 39 patients who had
detectable SNs (1.5 SNs per patient), 28 (46.7%) nodes
were found at level 12, 10 (16.7%) nodes were located in
the mediastinum, 11 (18.3%) nodes were found at level 11,
7 (11.7%) nodes were found at level 10, and only 4 (6.7%)
nodes were found at level 13. The lobar lymph nodes were
identified as SNs more frequently than the other lymph
nodes. Among the 10 patients with mediastinal sentinel
lymph nodes, 7 had SNs in both the mediastinal and hilar
regions. The remaining 3 patients had SNs only among the
mediastinal nodes (level 5 in 2 patients with primary tumors
located in the left upper lobe and level 4 in one patient with
a primary tumor located in the right upper lobe).
The most common site of the SN in patients with primary
tumors located in the right upper lobe was at level 12u
(61.0%, Figure 2). Two (33.3%) of six patients with primary
tumors in the right middle lobe each had SNs at levels 11s,
11i, and 12. The most common SNs in patients with primary
tumors of the right lower lobe were found at level 12l
(54%). Six (50%) of the 12 patients with primary tumors in
the left superior division and SNs had their sentinel lymph
nodes at level 12u, whereas 4 (33%) had these nodes at level
5. Four (40%) of the 10 patients with a primary tumor at the
left lingular division and SNs had their nodes in level 11.
One each of the 3 patients with primary tumors in the left
lower lobe and SNs had the sentinel lymph node at levels
12l, 10, and 4.
TABLE 1. Characteristics of patients with and without SNs
SN present SN absent P value
No. of patients 39 23
Age (y) 63 12 68 9 .03
Male/female 21/18 11/12 .65
Tumor size (mm) 24 14 23 14 .42
Lung function tests
VC (L) 2.89 0.88 3.04 0.77 .47
% VC 103.0 19.3 104.1 12.3 .78
FEV1.0 (L) 2.28 0.79 2.22 0.73 .76
FEV1.0% 81.2 8.1 74.5 11.0 .02
Primary location
RUL 13 5 .39
RML 4 1
RLL 7 4
LSD 8 6
LLD 5 2
LLL 2 5
Histology
Ad 28 19 .22
Sq 10 3
Adsq. 0 1
pN status
pN0 29 22 .09
pN1 5 1
pN2 5 0
Procedure
Lobectomy 33 17 .35
Segmentectomy 5 6
VC, Vital capacity; %VC, percent VC relative to the predicted value; FEV1.0,
forced expiratory volume in 1 second, FEV1.0%; FEV1.0/forced vital capac-
ity; RUL, right upper lobe; RML, right middle lobe; RLL, right lower lobe;
LSD, left superior division; LLD, left lingular division; LLL, left lower lobe;
Ad, adenocarcinoma; Sq, squamous cell carcinoma; Adsq, adenosqua-
mous cell carcinoma.
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Discussion
During the last decades of the 20th century, Japanese sur-
geons have shown interest in evaluating the survival benefit
of systematic lymphadenectomy in patients with lung can-
cer, and they have emphasized the excellent palliative ef-
fect, low operative mortality, and acceptable survival
among patients treated in this way.3,4 However, Izbicki and
colleagues5 performed a randomized trial in which radical
systematic lymphadenectomy was compared with limited
lymph node dissection of interlobar, peribronchial, and hilar
nodes (representing levels 10, 11, and 12) for clinical N0 or
N1 lung cancer. According to their data, radical systematic
mediastinal lymphadenectomy did not influence either dis-
ease-free survival or overall survival in patients with pN0
disease, and limited dissection caused less morbidity than
radical systematic dissection. It is difficult to identify pa-
tients who are potentially curable by means of limited node
dissection, even with CT scanning, magnetic resonance
imaging, and positron emission tomographic scanning.
Identification of the SN, which is the first draining node
from a primary lesion, has been used to individualize lymph
node dissection for melanoma,1 but application of this con-
cept to lung cancer is still controversial. The safety and
efficacy of the SN technique has already been documented
in patients with lung cancer.6-10 Liptay and coworkers7
performed intraoperative radionuclide SN mapping in pa-
tients with lung cancer and established the feasibility of this
technique, providing the basis for the evolving field of SN
mapping in lung tumors. Recently, Schmidt and associates8
used technetium-99m sulfur colloid and achieved an iden-
tification rate for sentinel lymph nodes of more than 80%.
Nomori and colleagues9 used technetium-99m tin colloid to
identify SNs in patients with lung cancer undergoing cura-
tive resection plus mediastinal lymph node dissection, and
their identification rate was 87%. These reports have several
similarities: (1) the identification rate of sentinel lymph
nodes was more then 80% by using radioisotopes; (2) me-
diastinal sentinel lymph nodes were found in 20% to 35% of
patients; and (3) false-negative results were observed in less
than 5% of patients. The group of patients that has the most
potential to benefit from application of the SN concept is the
group with small tumors and clinically negative lymph
nodes because the incidence of nodal metastatic disease in
these patients has been reported to range between 15% and
20%.11 We investigated the validity of this concept for cT1
N0 M0 lung cancer by using a radioactive tracer to detect
the SN, and we found that it was possible to make an
accurate intraoperative diagnosis and provide minimally
invasive surgical treatment tailored to the individual patient.
In patients with node-negative disease, on the basis of
imaging studies, the choice between limited lymph node
dissection and systematic lymphadenectomy could be de-
termined by the distribution of SNs.
Liptay and associates7 have noted a lower success rate of
the SN technique in patients with large necrotic tumors, as
well as in those with hilar and mediastinal adenopathy.
Larger necrotic tumors might be associated with changes to
the lymphatic and vascular supply, whereas established
adenopathy might cause efferent lymphatic obstruction.
Likewise, grossly enlarged lymph nodes that are clinically
positive should be routinely removed for accurate staging
and to ensure complete resection. We noted that the
FEV1.0% of patients without SNs was significantly lower
than that of patients with SNs. Nomori and colleagues9 also
reported that patients with chronic obstructive pulmonary
disease were less likely to have identifiable SNs. One pos-
sible explanation would be a decrease of lymphatic vessels
along with the loss of alveoli and functional lung tissue that
occurs as a result of emphysema.
Among the hilar lymph nodes, SNs were most frequently
identified at level 12. The reason for the lower frequency of
SNs at levels 11 and 10 can be explained by the fact that
Figure 2. Locations of sentinel lymph nodes in relation to the
primary tumor. Filled circles indicate a high incidence (>50%) of
SNs, shaded circles indicate a moderate incidence (>30%), and
open circles indicate a low incidence (<30%).
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these nodes are located further away from the primary
tumor than level 12 nodes. However, although level 13 was
nearer to the primary tumor than level 12, there were fewer
SNs at this level than at the latter. This observation is
similar to previous findings, which have demonstrated that
lymph node metastases of lung cancer are more frequent at
level 12 than at level 13.12,13 It is possible that some of the
lymph flow passes through lymphatic vessels beneath the
visceral pleura and goes to level 12 nodes but not level 13
nodes. The lungs have an extensive network of lymphatic
vessels in the loose connective tissue beneath the visceral
pleura, as well as in the connective tissue of the interlobular
septa and in the peribronchial vascular sheaths.14 Collec-
tions of lymphatic cells might be seen along the course of
these lymphatic channels and within the bronchi, but actual
intrapulmonary lymph nodes are infrequent in contrast to
the common detection of bronchopulmonary nodes. The
extensive subpleural networks are primarily drained by
channels in the interlobular septa to the hilar region, but
direct connections to the mediastinum have also been re-
corded. Mediastinal lymph node stations contained the sen-
tinel lymph nodes in 10 (25.6%) of 39 patients, and 3 (7.7%)
patients had SNs only in the mediastinal nodes (level 5 in 2
patients with primary tumors located in the left upper lobe
and level 4 in one patient with a primary tumor located in
the right upper lobe). Our study showed that the lymphatic
route to each mediastinal lymph node station was specific
for each lobe (ie, lymph flowed from the right upper lobe to
level 4 and from the left superior division to level 5). This
finding is supported by previous reports, which have shown
a similar prevalence of mediastinal lymph node metastases
from each lobe.11,12,15,16 Riquet and colleagues17 reported
the existence of direct lymphatic channels running from the
subpleural plexus of the lobar segments to various medias-
tinal lymph nodes without passing through the bronchopul-
monary nodes. These direct channels were observed in
36.3% and 38.6% of the right and left upper lobes, respec-
tively, being more frequent than in 22.3% and 21.1% of the
right and left lower lobes, respectively. This skip metastasis
pattern of drainage occurs more frequently in upper lobe
tumors and adenocarcinomas.17,18 In our study SNs were
found in the mediastinum of 22% and 33% of patients with
tumors in the right upper lobe and left superior division,
respectively. The intraoperative identification of SNs might
allow more accurate characterization of these unique pat-
terns of tumor lymphatic drainage. Although the SN tech-
nique might not be useful to separate patients requiring full
mediastinal node dissection from those needing sampling or
no dissection, the information gained from detailing the
actual nodal drainage of each tumor will continue to blur the
lines between N1 and N2 disease, leading to reconsideration
of the mechanism of nodal metastasis.
In Japan the use of radioisotopes is strictly limited to
designated areas, and therefore intraoperative injection is
impractical. The benefits of preoperative tumor injection on
the night before surgical intervention include better logistic
coordination with the nuclear medicine section and better
radiation safety. These advantages are balanced by the pa-
tient requiring a separate procedure and the small (but real)
risk of pneumothorax, bleeding, and tumor seeding along
the needle track.19 However, a comparison of previous
reports suggests that the use of sulfur colloid or tin colloid
and preoperative injection or intraoperative injection do not
make a significant difference to SN mapping.6,7,9 The tech-
nique that will ultimately be used is still unclear because
currently available data show that both methods achieve
reasonable SN detection rates. In our study successful ra-
dionuclide migration occurred in 39 (62.9%) of 62 patients
with primary lung cancer, which was a lower identification
rate than previous reports of more than 80%. The reason for
this difference in the identification rates is not clear. We
need to make further efforts to increase the identification
rate of SNs. In this study we injected 4 mCi of radioisotope
on the day before surgical intervention, which was twice the
radioisotope dose for intraoperative injection. Nomori and
colleagues9 reported that 8 mCi of radioisotope could
achieve a satisfactory identification rate of more than 85%
for SNs using the same technique as ours (ie, reference CT
scans and injection on the day before the operation). There-
fore an increase in the dosage of radioisotope injected could
probably increase the identification rate.
Okada and coworkers11 reported that segmentectomy
with mediastinal lymph node dissection for lung cancer less
than 2 cm in size and clinical N0 stage achieved a 5-year
survival similar to that seen after lobectomy. However, their
procedure required intraoperative pathologic diagnosis of
all the dissected lymph nodes, including the mediastinal
nodes, whereas our procedure could reduce the number of
lymph nodes examined during the operation. Identification
of the SN could be useful as an indication for segmentec-
tomy. If all the dissected hilar or mediastinal SNs reveal
no metastasis, segmentectomy could be adequate for cur-
ative resection, especially in patients with small lung
cancers.
In conclusion, intraoperative SN mapping by means of
preoperative injection of technetium-99–labeled colloid is
highly accurate in patients with cT1 N0 M0 lung cancer, and
thoracic surgeons might eventually become more confident
in withholding or proceeding to more radical nodal dissec-
tion on the basis of intraoperative SN data. Although we
have to make a continuous effort to increase the SN iden-
tification rate, sentinel lymph node biopsy in patients with
cT1 N0 M0 lung cancer could reduce the need for systemic
mediastinal lymph node dissection.
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